COMP <GO>
IONS vs LGND // EV/EBITDA & P/E VALUATION
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Ligand Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: IONS 3
— LGND 8
■ METRIC PARITY
LAST: $41.24 (-5.24%) • MKT CAP: $7.23B
valuation
—
LAST: $307.02 (-4.87%) • MKT CAP: $6.43B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. LGND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | LGND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 3.00% | -23.90 | LGND | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | 0.77% | -5.11 | LGND | /fcf-yield <GO> |
| Operating Margin | -40.40% | 15.30% | -55.70 | LGND | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 46.40% | -86.80 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 60.40% | -26.60 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 8.40 | -7.32 | LGND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.6 | 61.9 | -18.30 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.07 | +0.02 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 42.7x | -20.70 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.23B | $6.43B | $798.1M | IONS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | LGND REV | IONS GROSS % | LGND GROSS % | IONS FCF | LGND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $268.1M | 98.3% | — | -$320.0M | $48.9M |
| FY 2024 | $705.1M | $167.1M | 98.4% | — | -$546.2M | $95.2M |
| FY 2023 | $787.6M | $131.3M | — | — | -$343.0M | $43.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
LGND // BETA 1.07